Cost-Effectiveness Analysis of Pharmacogenetic-Guided Warfarin Dosing in Thailand

被引：0
|
作者：
Chong, Huey Yi [1 ]
Saokaew, Surasak [2 ,3 ]
Dumrongprat, Kuntika [4 ]
Permsuwan, Unchalee [5 ]
Wu, David Bin-Chia [1 ]
Sritara, Piyamitr [6 ]
Chaiyakunapruk, Nathorn [1 ,3 ,7 ,8 ]
机构：
[1] Monash Univ Malaysia, Sch Pharm, Selangor, Malaysia
[2] Univ Phayao, Sch Pharmaceut Sci, Ctr Hlth Outcomes Res & Therapeut Safety COHORTS, Phayao, Thailand
[3] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, CPOR, Phitsanulok, Thailand
[4] Cardiff Univ, Welsh Sch Pharm, Cardiff CFJ0 3XF, S Glam, Wales
[5] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, Chiang Mai 50000, Thailand
[6] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med, Bangkok 10400, Thailand
[7] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[8] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia
来源：
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS | 2014年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Ab27
引用
收藏
页码：S2 / S2
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of pharmacogenetic-guided warfarin dosing in Thailand
    Chong, Huey Yi
    Saokaew, Surasak
    Dumrongprat, Kuntika
    Permsuwan, Unchalee
    Wu, David Bin-Chia
    Sritara, Piyamitr
    Chaiyakunapruk, Nathorn
    [J]. THROMBOSIS RESEARCH, 2014, 134 (06) : 1278 - 1284
  • [2] Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
    Verhoef, T. I.
    Redekop, W. K.
    Langenskiold, S.
    Kamali, F.
    Wadelius, M.
    Burnside, G.
    Maitland-van der Zee, A-H
    Hughes, D. A.
    Pirmohamed, M.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (05): : 478 - 484
  • [3] Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
    T I Verhoef
    W K Redekop
    S Langenskiold
    F Kamali
    M Wadelius
    G Burnside
    A-H Maitland-van der Zee
    D A Hughes
    M Pirmohamed
    [J]. The Pharmacogenomics Journal, 2016, 16 : 478 - 484
  • [4] Cost-Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation
    Verhoef, Talitha I.
    Redekop, William K.
    Veenstra, David L.
    Thariani, Rahber
    Beltman, Peter A.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 328 - 329
  • [5] Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy IN RESPONSE
    Eckman, Mark H.
    Rosand, Jonathan
    Greenberg, Steven M.
    Gage, Brian F.
    [J]. ANNALS OF INTERNAL MEDICINE, 2009, 151 (01) : 71 - 71
  • [6] Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
    Verhoef, Talitha I.
    Redekop, William K.
    Veenstra, David L.
    Thariani, Rahber
    Beltman, Peter A.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    [J]. PHARMACOGENOMICS, 2013, 14 (08) : 869 - 883
  • [7] Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?
    Scott, Stuart A.
    Lubitz, Steven A.
    [J]. PHARMACOGENOMICS, 2014, 15 (06) : 719 - 722
  • [8] Pharmacogenetic-guided selection of oral anticoagulants: a cost-effectiveness analysis.
    You, Joyce
    [J]. PHARMACOTHERAPY, 2014, 34 (10): : E218 - E218
  • [9] Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    M Verbelen
    M E Weale
    C M Lewis
    [J]. The Pharmacogenomics Journal, 2017, 17 : 395 - 402
  • [10] Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    Verbelen, M.
    Weale, M. E.
    Lewis, C. M.
    [J]. PHARMACOGENOMICS JOURNAL, 2017, 17 (05): : 395 - 402
12345